Filtered By:
Condition: Pneumonia
Infectious Disease: SARS
This page shows you your search results in order of date.
Order by Relevance | Date
Total 73 results found since Jan 2013.
The U.S. Scientist At the Heart of COVID-19 Lab Leak Conspiracies Is Still Trying to Save the World From the Next Pandemic
Ralph Baric stepped onto the auditorium stage at the University of North Carolina, Chapel Hill, and looked out at the sparse audience that had come to hear him speak. On the large projector screen hanging behind him, the following words appeared: How Bad the Next Pandemic Could Be, What Might It Look Like, and Will We be Ready. The date was May 29, 2018.
“Well, I have to admit I’m a little worried about giving this talk,” Baric said. “The reason is being labelled a harbinger of doom.” The screen shifted, and images of the four horsemen of the apocalypse—Death, Famine, War, and Plague&mda...
Source: TIME: Health - July 11, 2023 Category: Consumer Health News Authors: Dan Werb Tags: Uncategorized COVID-19 feature freelance Source Type: news
Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al
We read with great interest the Global Rheumatology Alliance report on COVID-19 on biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA).1 The first important result of the registry database is that B-cell depletion, by compromising the primary antibody response, increases the severity of infected patients. Considering the critical role of B cells in the adaptive immune response, this sounds quite correct.2 Even the data on interleukin 6 and tumour necrosis factor (TNF) inhibitors appear quite understandable considering the systemic inflammation raised by SARS-CoV-2 infe...
Source: Annals of the Rheumatic Diseases - June 12, 2023 Category: Rheumatology Authors: Gremese, E., Ferraccioli, G. Tags: ARD, COVID-19 Correspondence Source Type: research
Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19
Most severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals are asymptomatic or only exhibit mild disease. In about 10% of cases, the infection leads to hypoxemic pneumonia, although it is much more rare in children.
Source: Journal of Allergy and Clinical Immunology - September 13, 2022 Category: Allergy & Immunology Authors: Hassan Abolhassani, Samaneh Delavari, Nils Landegren, Sima Shokri, Paul Bastard, Likun Du, Fanglei Zuo, Reza Hajebi, Farhad Abolnezhadian, Sara Iranparast, Mohammadreza Modaresi, Ahmad Vosughimotlagh, Fereshte Salami, Maribel Aranda-Guill én, Aurélie Co Source Type: research
Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19
AbstractSince the start of the coronavirus disease 2019 (COVID-19) pandemic, important insights have been gained into virus biology and the host factors that modulate the human immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 displays a highly variable clinical picture that ranges from asymptomatic disease to lethal pneumonia. Apart from well-established general risk factors such as advanced age, male sex and chronic comorbidities, differences in host genetics have been shown to influence the individual predisposition to develop severe manifestations of COVID-19. These differen...
Source: Genome Medicine - August 19, 2022 Category: Genetics & Stem Cells Source Type: research
Spontaneous NLRP3 inflammasome-driven IL-1- β secretion is induced in severe COVID-19 patients and responds to anakinra treatment
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in a severe pneumonia associated with elevation of blood inflammatory parameters, reminiscent of cytokine storm syndrome. Steroidal anti-inflammatory therapies have shown efficacy in reducing mortality in critically ill patients; however, the mechanisms by which SARS-CoV-2 triggers such an extensive inflammation remain unexplained.
Source: Journal of Allergy and Clinical Immunology - July 11, 2022 Category: Allergy & Immunology Authors: Arinna Bertoni, Federica Penco, Hilaria Mollica, Paola Bocca, Ignazia Prigione, Anna Corcione, Davide Cangelosi, Francesca Schena, Genny Del Zotto, Adriana Amaro, Noemi Paladino, Emanuele Pontali, Marcello Feasi, Sara Signa, Marta Bustaffa, Roberta Caorsi Source Type: research
Exhaled nitric oxide is decreased in Sars-Cov-2 infection
Due to the broad spectrum of Sars-Cov-2 infection ´s clinical manifestations, some biomarkers have been investigated to predict its severity and evolution. Exhaled nitric oxide,(FeNO), a T2 inflammatory marker, has also been study in respiratory infections (viral, bacterial and fungal) with or without pneumonia .
Source: Journal of Allergy and Clinical Immunology - February 1, 2022 Category: Allergy & Immunology Authors: Diana Betancor, Marcela Valverde Monge, Blanca Barroso Garc Ãa, Joaquin Sastre Source Type: research
Psychological Impacts of COVID-19 on people with Asthma, Allergic Rhinitis and Food Allergy
Coronavirus disease of 2019 (COVID-19) is a respiratory illness characterized by fever, cough, dyspnea, fatigue, and lymphopenia. Severe COVID-19 complications can manifest as viral pneumonia and may lead to severe acute respiratory syndrome and, in some cases, death [1, 2]. As of December 2021, SARS-CoV-2 has caused more than 263,300,000 infections, and over 5,221,000 deaths. Since December 2020, over 8,033,000,000 vaccine doses have been administered [3]. A global systematic review conducted during the COVID-19 pandemic of the general public's psychological outcomes found relatively high rates of anxiety (6.33% to 50.9%)...
Source: Annals of Allergy, Asthma and Immunology - December 28, 2021 Category: Allergy & Immunology Authors: Alyssa G. Burrows, Anne K. Ellis Tags: Review Source Type: research
Asthma and COVID-19: an update
As the world faces the coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, concerns have been raised that asthma patients could be at increased risk of SARS-CoV-2 infection and disease severity. However, it appears that asthma is not an independent risk factor for both. Furthermore, asthma is not over-represented in hospitalised patients with severe pneumonia due to SARS-CoV-2 infection and there was no increased risk of asthma exacerbations triggered by SARS-CoV-2. There is accumulating evidence that asthma phenotypes and comorbidities are important f...
Source: European Respiratory Review - December 15, 2021 Category: Respiratory Medicine Authors: Adir, Y., Saliba, W., Beurnier, A., Humbert, M. Tags: Respiratory clinical practice, Asthma and allergy COVID-19 Reviews Source Type: research
Severe asthma biologic treatment in the era of COVID-19 - case series
Conclusions: Only a minority of this population tested positive for COVID-19 and none of them developed serious disease, supporting the evidence that both severe type-2 asthma and its targeted treatment do not convey increased risk for disease. However, additional studies regarding long-term complications should also be performed.
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Costa, P. M. N., Loureiro, C. C. Tags: Allergy and immunology Source Type: research
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med. 2021 Oct 18:S2213-2600(21)00384-2. doi: 10.1016/S2213-2600(21)00384-2. Online ahead of print.ABSTRACTBACKGROUND: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19.METHODS: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospita...
Source: Respiratory Care - October 21, 2021 Category: Respiratory Medicine Authors: Andre C Kalil Aneesh K Mehta Thomas F Patterson Nathaniel Erdmann Carlos A Gomez Mamta K Jain Cameron R Wolfe Guillermo M Ruiz-Palacios Susan Kline Justino Regalado Pineda Anne F Luetkemeyer Michelle S Harkins Patrick E H Jackson Nicole M Iovine Victor F Source Type: research
The course of COVID-19 in patients with severe asthma receiving biological treatment
Conclusion: Severe asthma itself seems to be a risk factor for COVID-19, whether biological treatment has a role in the disease course needs further research.PMID:34669544 | DOI:10.1080/02770903.2021.1996599
Source: Journal of Asthma - October 20, 2021 Category: Respiratory Medicine Authors: G ülseren Tuncay Mehmet Erdem Cakmak Ozge Can Bostan Saltuk Bugra Kaya Ebru Damadoglu G ül Karakaya Ali Fuat Kalyoncu Source Type: research
